RxIndia
Loading clinical data...
Loading clinical data...
Authoritative Clinical Reference
| Parameter | Recommendation |
|
Starting dose
|
1 mg once daily, preferably in the morning |
|
Titration
|
If response inadequate after 2–3 weeks, increase to 1 mg twice daily |
|
Usual maintenance dose
|
1–2 mg daily, in 1 or 2 divided doses |
|
Maximum dose
|
2 mg/day |
| Parameter | Recommendation |
|
Starting dose
|
1 mg once daily |
|
Titration
|
May increase to 1 mg twice daily based on response |
|
Usual maintenance dose
|
1–2 mg daily in divided doses |
|
Maximum dose
|
2 mg/day |
|
Duration
|
Long-term as per blood pressure control |
| Renal Function | Recommendation |
| eGFR ≥30 mL/min/1.73m² | No dose adjustment required |
| eGFR 15–29 mL/min/1.73m² | Start with 1 mg once daily; use with caution; monitor blood pressure and for signs of bradycardia |
| eGFR <15 mL/min/1.73m² | Avoid unless under specialist supervision |
| Haemodialysis | Limited data; use with caution under specialist guidance |
| Severity | Recommendation |
| Mild impairment | No dose adjustment required |
| Moderate impairment | Use with caution; initiate at 1 mg once daily; monitor for CNS adverse effects |
| Severe impairment | Avoid use — increased CNS exposure expected; no safety data available |
| Consideration | Recommendation |
| Overall safety | Insufficient human data; use with caution |
| Risk | Potential for fetal effects based on mechanism; limited safety information |
| When it may be used | Only if benefit clearly outweighs risk and preferred alternatives are poorly tolerated |
| Preferred alternatives | Methyldopa or labetalol are better established in Indian obstetric practice |
| Monitoring | Maternal blood pressure, fetal growth, and wellbeing if used |
| Consideration | Recommendation |
| Compatibility | Limited data; compatibility uncertain |
| Drug levels in milk | Likely low levels based on pharmacokinetic properties |
| Preferred alternatives | Labetalol or nifedipine during breastfeeding |
| Infant monitoring | Sedation, hypotonia, feeding difficulty, poor weight gain |
| Consideration | Recommendation |
| Starting dose | 1 mg once daily |
| Titration | Slower titration recommended — increased sensitivity to CNS effects |
| Risks | Drowsiness, dizziness, orthostatic hypotension, falls |
| Monitoring | Blood pressure (including orthostatic), renal function periodically, mental status assessment |
| Interacting Drug | Effect / Mechanism | Recommendation |
| Beta-blockers | Additive bradycardia and hypotension; risk of severe rebound hypertension if either drug abruptly withdrawn |
Avoid abrupt withdrawal of either agent; taper gradually
|
| Tricyclic antidepressants | May antagonise antihypertensive effect via alpha-adrenergic blockade |
Avoid concurrent use
|
| MAO inhibitors | Theoretical risk of hypertensive reaction |
Avoid combination
|
| CNS depressants (benzodiazepines, alcohol, opioids) | Enhanced sedative effects |
Avoid or use with extreme caution
|
| Interacting Drug | Effect / Mechanism | Recommendation |
| Diuretics | Additive antihypertensive effect | Monitor blood pressure, especially in volume-depleted patients |
| ACE inhibitors/ARBs | Additive antihypertensive effect | Generally safe; monitor for hypotension when initiating combination |
| Calcium channel blockers | Additive blood pressure lowering | Monitor blood pressure; may require dose adjustment |
| Digoxin | Additive bradycardia risk | Monitor heart rate |
| Adverse Effect | Clinical Note |
| Severe bradycardia | Rare; discontinue if symptomatic |
| Depression or worsening of psychiatric symptoms | Monitor mental status; discontinue if significant |
| Rebound hypertension | If abruptly discontinued; may require hospitalisation if severe |
| Hypersensitivity reactions | Rare; discontinue immediately |
| Syncope | Due to excessive hypotension; more common in elderly |
| Phase | Parameters |
|
Baseline
|
Blood pressure, heart rate, renal function, mental health history |
|
After initiation/dose change
|
Blood pressure after 1–2 weeks; assess for sedation or depression symptoms |
|
Long-term
|
Quarterly blood pressure monitoring; periodic renal function assessment; mental status evaluation especially in elderly |
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Help us improve our clinical database for the medical community.